AEON
AEON Biopharma, Inc. AMEX Listed Jul 24, 2023$0.67
-0.83%
vs $0.67
Mkt Cap $6.6M
52w Low $0.66
1.5% of range
52w High $1.40
50d MA $0.85
200d MA $0.95
P/E (TTM)
-0.2x
EV/EBITDA
—
P/B
—
Debt/Equity
-0.7x
ROE
197.4%
P/FCF
-0.4x
RSI (14)
24.50
ATR (14)
$0.05
Beta
0.73
50d MA
$0.85
200d MA
$0.95
Avg Volume
53.2K
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
4040 Macarthur Boulevard · Newport Beach, CA 92614 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.20 | -3.72 | -1714.6% | 0.99 | +21.3% | -0.5% | -0.7% | -9.2% | +2.4% | +3.0% | — |
| Nov 14, 2025 | AMC | -0.43 | -0.39 | +9.3% | 0.90 | -1.0% | -3.8% | +10.5% | -2.1% | -12.8% | +1.2% | — |
| Aug 12, 2025 | AMC | — | -0.60 | — | 0.69 | -2.9% | +16.1% | -2.5% | -1.5% | -1.7% | -3.2% | — |
| May 14, 2025 | AMC | -13.67 | -0.09 | +99.3% | 0.50 | -6.6% | -1.0% | +1.4% | +1.8% | +0.0% | -4.5% | — |
| Mar 24, 2025 | AMC | -12.95 | 3.75 | +129.0% | 0.72 | +2.2% | -7.3% | +4.3% | -8.6% | -7.3% | -2.2% | — |
| Nov 13, 2024 | AMC | -11.51 | -11.51 | +0.0% | 49.69 | +1.4% | -11.4% | +0.9% | -3.3% | -2.8% | -2.8% | — |
| Aug 12, 2024 | AMC | -13.67 | -11.51 | +15.8% | 71.99 | +4.0% | -1.0% | +2.0% | +4.0% | -2.9% | -2.0% | — |
| May 14, 2024 | AMC | -22.30 | -20.14 | +9.7% | 117.36 | +0.0% | -3.1% | -5.1% | +2.0% | +11.1% | -2.9% | — |
| Mar 29, 2024 | AMC | -0.40 | -0.71 | -77.5% | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -40.37 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.80 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 8 | Aegis Capital | Maintains | Buy → Buy | — | $0.94 | $0.97 | +3.7% | -1.6% | +12.0% | +9.7% | -5.3% | +9.3% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $75.60 | $75.60 | +0.0% | -2.9% | +10.8% | -1.8% | +9.0% | +24.0% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $71.28 | $72.00 | +1.0% | +2.0% | +4.0% | -2.9% | -2.0% | -1.0% |
| Jul 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $79.20 | $77.40 | -2.3% | -5.5% | +1.9% | +32.1% | +62.9% | +25.4% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $108.00 | $114.48 | +6.0% | -4.0% | +9.7% | +3.8% | -4.9% | -0.6% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $117.36 | $117.36 | +0.0% | -3.1% | -5.1% | +2.0% | +11.1% | -2.9% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $122.40 | $126.00 | +2.9% | -4.1% | -2.5% | +11.3% | -6.2% | +4.2% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $496.08 | $493.20 | -0.6% | -1.5% | -3.7% | -28.7% | +1.3% | -8.9% |
No insider trades available.
8-K
AEON Biopharma, Inc. -- 8-K Filing
This 8-K filing from AEON Biopharma lacks material event disclosure details, providing only standard signature language without information relevant to investor decision-making.
Jun 17
8-K · 2.02
!! High
AEON Biopharma, Inc. -- 8-K 2.02: Earnings Results
AEON Biopharma reported Q1 2026 financial results, though the filing provides no details about revenue, profitability, or operational performance metrics relevant to investment decisions.
May 14
8-K
Unknown — 8-K Filing
AEON faces delisting risk if it fails to meet NYSE American's standards by August 2026, creating significant uncertainty for shareholders and potentially triggering forced selling pressure.
Apr 3
8-K
Unknown — 8-K Filing
AEON's biosimilar prabotulinumtoxin A advance toward full BOTOX market entry could unlock significant revenue from the multi-billion dollar aesthetics market, making clinical/regulatory progress critical for shareholders.
Mar 30
8-K · 5.02
!!! Very High
AEON Biopharma, Inc. -- 8-K 5.02: Executive Change
AEON Biopharma appointed John Bencich as Chief Financial Officer, signaling leadership changes that could affect the company's financial strategy and investor confidence going forward.
Mar 9
Institutional (13F) — Top 10
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Dauntless Investment Group, Llc | 2,527,775 | $2M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 90,529 | $89K | New | Mar 2026 |
| 3 | Blue Owl Capital Holdings Lp | 42,353 | $42K | Reduced | Mar 2026 |
| 4 | Ubs Group Ag | 4,182 | $4K | Added | Mar 2026 |
| 5 | Steward Partners Investment Advisory, Llc | 1,100 | $1K | Added | Mar 2026 |
| 6 | Wolff Wiese Magana Llc | 567 | $559 | — | Mar 2026 |
| 7 | Morgan Stanley | 300 | $330 | — | Dec 2025 |
| 8 | Dupont Capital Management Corp | 170 | $167 | — | Mar 2026 |
| 9 | Wells Fargo & Company/mn | 90 | $89 | New | Mar 2026 |
| 10 | Danske Bank A/s | 1 | $1 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 10
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | WisdomTree Emerging Markets SmallCap Dividend Fund | 2,450,200 | $647K | Mar 2026 |
| 2 | Avantis Emerging Markets Equity ETF | 1,996,300 | $646K | Feb 2026 |
| 3 | Fidelity Extended Market Index Fund | 40,999 | $46K | Feb 2026 |
| 4 | Avantis Emerging Markets Equity Fund | 118,600 | $38K | Feb 2026 |
| 5 | Avantis Emerging Markets Value ETF | 66,900 | $22K | Feb 2026 |
| 6 | Avantis Emerging Markets Small Cap Equity ETF | 46,600 | $15K | Feb 2026 |
| 7 | Avantis Responsible Emerging Markets Equity ETF | 42,800 | $14K | Feb 2026 |
| 8 | Avantis Emerging Markets ex-China Equity ETF | 40,300 | $13K | Feb 2026 |
| 9 | Fidelity Series Total Market Index Fund | 11,192 | $13K | Feb 2026 |
| 10 | Fidelity Total Market Index Fund | 3,072 | $3K | Feb 2026 |
Valuation
Market Cap
$6.6M
Enterprise Value
$38.2M
P/E (TTM)
-0.17x
Forward P/E
—
PEG Ratio
0.00x
P/B
—
P/S
—
P/FCF
-0.38x
EV/EBITDA
—
Shares Out
9.9M
Financials (TTM)
Revenue
$0
Net Income
-$39.2M
EBITDA
-$16.8M
Free Cash Flow
-$17.3M
Op Cash Flow
-$17.3M
EPS Basic
$-3.95
EPS Diluted
$-3.95
EPS Forward
$-1.96
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$5.6M
Total Liab.
$60.6M
Total Equity
-$55.0M
Cash
$3.0M
LT Debt
$34.6M
Book Value/Sh
$-5.55
Debt/Equity
-0.65x
Current Ratio
0.49
Quick Ratio
0.49
Returns & Growth
ROE
197.4%
ROA
-705.4%
ROIC
1557.8%
Rev Growth YoY
+0.0%
EPS Growth YoY
-105.1%
Price Returns
2W
-6.2%
1M
-18.6%
3M
-32.9%
6M
-11.3%
12M
+30.4%
Technicals
52W High
$1.40
52W Low
$0.66
50d MA
$0.85
200d MA
$0.95
RSI (14)
24.50
ATR (14)
$0.05
Beta
0.73
Avg Volume
53K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 4:18pm
· Source: financialmodelingprep.com